» Articles » PMID: 23685825

Reductions in Serum Lipids with a 4-year Decline in Serum Perfluorooctanoic Acid and Perfluorooctanesulfonic Acid

Overview
Journal Epidemiology
Specialty Public Health
Date 2013 May 21
PMID 23685825
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several epidemiological cross-sectional studies have found positive associations between serum concentrations of lipids and perfluorooctanoic acid (PFOA, or C8). A longitudinal study should be less susceptible to biases from uncontrolled confounding or reverse causality.

Methods: We investigated the association between within-individual changes in serum PFOA and perfluorooctanesulfonic acid (PFOS) and changes in serum lipid levels (low-density lipoprotein [LDL] cholesterol, high-density lipoprotein cholesterol, total cholesterol, and triglycerides) over a 4.4-year period. The study population consisted of 560 adults living in parts of Ohio and West Virginia where public drinking water had been contaminated with PFOA. They had participated in a cross-sectional study in 2005-2006, and were followed up in 2010, by which time exposure to PFOA had been substantially reduced.

Results: Overall serum concentrations of PFOA and PFOS fell by half from initial geometric means of 74.8 and 18.5 ng/mL, respectively, with little corresponding change in LDL cholesterol (mean increase 1.8%, standard deviation 26.6%). However, there was a tendency for people with greater declines in serum PFOA or PFOS to have greater LDL decrease. For a person whose serum PFOA fell by half, the predicted fall in LDL cholesterol was 3.6% (95% confidence interval = 1.5-5.7%). The association with a decline in PFOS was even stronger, with a 5% decrease in LDL (2.5-7.4%).

Conclusions: Our findings from this longitudinal study support previous evidence from cross-sectional studies of positive associations between PFOA and PFOS in serum and LDL cholesterol.

Citing Articles

Per- and Polyfluoroalkyl Substances and Outcomes Related to Metabolic Syndrome: A Review of the Literature and Current Recommendations for Clinicians.

Hall A, Braun J Am J Lifestyle Med. 2025; 19(2):211-229.

PMID: 39981556 PMC: 11836584. DOI: 10.1177/15598276231162802.


Exposure to specific polyfluoroalkyl chemicals is associated with cardiovascular disease in US adults: a population-based study.

Xiao W, Jian G, Ma F, Li H, Yang X, Zhang H Front Cardiovasc Med. 2025; 11():1487956.

PMID: 39850378 PMC: 11754394. DOI: 10.3389/fcvm.2024.1487956.


Per- and polyfluoroalkyl substances, apolipoproteins and the risk of coronary heart disease in US men and women.

Zhu L, Liu B, Hu Y, Wang M, Furtado J, Rimm E Environ Health. 2024; 23(1):108.

PMID: 39627728 PMC: 11613683. DOI: 10.1186/s12940-024-01147-2.


Perfluoroalkyl/Polyfluoroalkyl Substances: Links to Cardiovascular Disease Risk.

Schlezinger J, Gokce N Circ Res. 2024; 134(9):1136-1159.

PMID: 38662859 PMC: 11047059. DOI: 10.1161/CIRCRESAHA.124.323697.


All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980-2018).

Biggeri A, Stoppa G, Facciolo L, Fin G, Mancini S, Manno V Environ Health. 2024; 23(1):42.

PMID: 38627679 PMC: 11022451. DOI: 10.1186/s12940-024-01074-2.


References
1.
Frisbee S, Brooks Jr A, Maher A, Flensborg P, Arnold S, Fletcher T . The C8 health project: design, methods, and participants. Environ Health Perspect. 2010; 117(12):1873-82. PMC: 2799461. DOI: 10.1289/ehp.0800379. View

2.
Krey G, Braissant O, LHorset F, Kalkhoven E, Perroud M, Parker M . Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997; 11(6):779-91. DOI: 10.1210/mend.11.6.0007. View

3.
Rigamonti E, Chinetti-Gbaguidi G, Staels B . Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 2008; 28(6):1050-9. DOI: 10.1161/ATVBAHA.107.158998. View

4.
Glymour M, Weuve J, Berkman L, Kawachi I, Robins J . When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005; 162(3):267-78. DOI: 10.1093/aje/kwi187. View

5.
Kato K, Basden B, Needham L, Calafat A . Improved selectivity for the analysis of maternal serum and cord serum for polyfluoroalkyl chemicals. J Chromatogr A. 2010; 1218(15):2133-7. DOI: 10.1016/j.chroma.2010.10.051. View